RECORD // Company

NRX Pharmaceuticals, Inc.

Formerly: Big Rock Partners Acquisition Corp.

Built 2026-11-22T04:37:54Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Matched by name only, not merged (1)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

4 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-16 · accession 0001437749-26-037198

ItemValuePeriodFormFiledAccessionReport
Revenue$1,159,0003 months ended 2026-09-3010-Q2026-11-160001437749-26-0371982026-11-22 04:37 UTCReport an error
Net income (loss)$-2,175,0003 months ended 2026-09-3010-Q2026-11-160001437749-26-0371982026-11-22 04:37 UTCReport an error
Interest expense$239,0003 months ended 2026-09-3010-Q2026-11-160001437749-26-0371982026-11-22 04:37 UTCReport an error
Cash and cash equivalents$19,822,000at 2026-09-3010-Q2026-11-160001437749-26-0371982026-11-22 04:37 UTCReport an error

Negative as reported in the filing.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001719406
Ticker
NRXP
EIN
822844431
CUSIP
629444209
Record ID
sx:sec:0001719406

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

33 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-22 04:37 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-16SEC EDGAR company profile2026-11-22 04:37 UTCReport an error
State of incorporationDE2026-11-16SEC EDGAR company profile2026-11-22 04:37 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-22 04:37 UTCReport an error
Business address1201 ORANGE STREET, SUITE 600, WILMINGTON, DE, 198012026-11-16SEC EDGAR company profile2026-11-22 04:37 UTCReport an error
ExchangesNasdaq2026-11-16SEC EDGAR company profile2026-11-22 04:37 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$1,225,0002025-12-3110-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax2026-11-22 04:37 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-28,622,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-22 04:37 UTCReport an error
Total assets (at 2025-12-31)$12,956,0002025-12-3110-K, XBRL Assets2026-11-22 04:37 UTCReport an error
Stockholders' equity (at 2025-12-31)$-15,937,0002025-12-3110-K, XBRL StockholdersEquity2026-11-22 04:37 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$7,797,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 04:37 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-14,112,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 04:37 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2024-12-31)$02024-12-3110-K, XBRL PaymentsToAcquireProductiveAssets2026-11-22 04:37 UTCReport an error
Operating lease liabilities (at 2025-12-31)$631,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-22 04:37 UTCReport an error
Form D total offering amount (D filed 2025-03-07)$3,500,0002025-03-07D2026-11-22 04:37 UTCReport an error
Form D total amount sold (D filed 2025-03-07)$3,500,0002025-03-07D2026-11-22 04:37 UTCReport an error
Form D industry groupBiotechnology2025-03-07D2026-11-22 04:37 UTCReport an error
Form D revenue rangeDecline to Disclose2025-03-07D2026-11-22 04:37 UTCReport an error
Form D date of first sale2025-01-272025-03-07D2026-11-22 04:37 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-11-02)On October 30, 2026, NRx Pharmaceuticals, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (the “FDA”) has approved the Company’s Abbreviated New Drug Application (“ANDA”) for Preservative-Free Ketamine, ahead of the November 10, 2026 goal date established under the Generic Drug User Fee Amendments (“GDUFA”). The Company also hosted a conference call and live webcast at 8:30 a.m. Eastern Time on October 30, 2026 to discuss the approval. A copy of the press release announcing the approval is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Current Report on Form…2026-11-02SEC EDGAR 8-K 0001437749-26-034284 (text as filed, excerpt)2026-11-22 04:37 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-10-16)2026 Annual Meeting of Stockholders On October 16, 2026, the board of directors (the “Board”) of NRx Pharmaceuticals, Inc. (the “Company”) established December 17, 2026 as the date of the 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) and set October 28, 2026 as the record date for determining stockholders entitled to vote at the 2026 Annual Meeting. The 2026 Annual Meeting will be held at 10:00 a.m., Eastern Time, in a virtual-only format conducted by live webcast. Additional details regarding the 2026 Annual Meeting, including the matters to be voted upon and instructions for accessing the virtual meeting, will be set forth in the Company’s definitive proxy statement for…2026-10-16SEC EDGAR 8-K 0001437749-26-032828 (text as filed, excerpt)2026-11-22 04:37 UTCReport an error
8-K Item 1.01, Entry into a Material Definitive Agreement (filed 2026-10-05)On September 29, 2026, NRx Defense Systems, Inc. (“NRx Defense”), a subsidiary of NRx Pharmaceuticals, Inc. (the “Company”), entered into a prime contract (the “Contract”) with Defense Advanced Research Projects Agency (“DARPA”) pursuant to which NRx Defense was awarded a contract to conduct the Synaptic Plasticity Augmented Rapid Circuit Stimulation (“SPARC-TMS”) clinical trial. The Contract has an aggregate value of approximately $11.2 million, of which approximately $6.7 million has been initially obligated by DARPA, with additional funding subject to the availability of appropriations and DARPA’s exercise of funding options. The Contract has an 18‑month performance period and provides…2026-10-05SEC EDGAR 8-K 0001437749-26-032042 (text as filed, excerpt)2026-11-22 04:37 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-09-16)On September 15, 2026, NRx Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that it has received a written communication from the Director of Regulatory Operations of the FDA Office of Generic Drugs advising the Company that the amendment to its Abbreviated New Drug Application (ANDA), previously classified as a Major Amendment, has been reclassified as a Minor Amendment. The acknowledgement letter revised the GDUFA goal date to November 10, 2026, citing that the reclassified amendment will not require a substantial expenditure of FDA resources. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by…2026-09-16SEC EDGAR 8-K 0001437749-26-030492 (text as filed, excerpt)2026-11-22 04:37 UTCReport an error
Largest institutional holder #1 (13F as filed): B Group, Inc.$16,735,3272026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:37 UTCReport an error
Largest institutional holder #2 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$6,618,2702026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:37 UTCReport an error
Largest institutional holder #3 (13F as filed): AMERIPRISE FINANCIAL INC$3,798,4982026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:37 UTCReport an error
Largest institutional holder #4 (13F as filed): Balyasny Asset Management L.P.$3,655,9042026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:37 UTCReport an error
Largest institutional holder #5 (13F as filed): CITADEL ADVISORS LLC$2,781,3762026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:37 UTCReport an error
Largest institutional holder #6 (13F as filed): AdvisorShares Investments LLC$2,695,3842026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:37 UTCReport an error
Largest institutional holder #7 (13F as filed): COMMONWEALTH EQUITY SERVICES, LLC$1,858,5702026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:37 UTCReport an error
Largest institutional holder #8 (13F as filed): UBS Group AG$1,730,5402026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:37 UTCReport an error
Largest institutional holder #9 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$1,287,1022026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:37 UTCReport an error
Largest institutional holder #10 (13F as filed): BlackRock, Inc.$901,6812026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:37 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.